Loading...
Please wait, while we are loading the content...
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
| Content Provider | Europe PMC |
|---|---|
| Author | Rothenberg, S Michael Concannon, Kyle Cullen, Sarah Boulay, Gaylor Turke, Alexa B Faber, Anthony C Lockerman, Elizabeth L Rivera, Miguel N Engelman, Jeffrey A Maheswaran, Shyamala Haber, Daniel A |
| Editor | Davis, Roger |
| Copyright Year | 2015 |
| ISSN | 2050084X |
| Journal | eLife |
| Volume Number | 4 |
| PubMed Central reference number | PMC4384750 |
| PubMed reference number | 25686219 |
| e-ISSN | 2050084X |
| DOI | 10.7554/elife.06132 |
| Language | English |
| Publisher | eLife Sciences Publications, Ltd |
| Publisher Date | 2015-02-16 |
| Access Restriction | Open |
| Rights License | This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse and redistribution provided that the original author and source arecredited. © 2015, Rothenberg et al |
| Subject Keyword | targeted cancer therapy EGFR mutations SOX2 resistance lung cancer human mouse |
| Content Type | Text |
| Resource Type | Article |
| Subject | Neuroscience Immunology and Microbiology Medicine Biochemistry, Genetics and Molecular Biology |